UBS initiated coverage of Omega Healthcare (OHI) with a Buy rating and $50 price target The firm expects positive estimate revisions for the company, driven by better than expected future investment volumes and strong EBITDAR coverage. Omega should see upside to investment volumes, driven by a “broad” investment total addressable market, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OHI:
- Omega Healthcare: Strong Buy Rating Driven by Strategic Investments and Positive Market Trends
- Omega Healthcare price target raised to $48 from $46 at BofA
- Omega Healthcare price target raised to $45 from $42 at Scotiabank
- Omega Healthcare price target raised to $50 from $45 at Citi
- Omega Healthcare Investors Reports Strong Q3 2025 Earnings